761
Views
0
CrossRef citations to date
0
Altmetric
Original Articles: Clinical Oncology

Recurrence rate after radical prostatectomy following primary staging of high-risk prostate cancer with 68Ga-PSMA PET/CT

ORCID Icon, ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon & show all
Pages 1289-1294 | Received 29 May 2022, Accepted 22 Sep 2022, Published online: 05 Oct 2022

Figures & data

Figure 1. Flow chart of inclusion of high-risk prostate cancer patients treated by radical prostatectomy in the study. *Refers to treatment with antiandrogens, surgical or chemical castration therapy, 223Radium, and early or late chemotherapy (most commonly Docetaxel or Cabazitaxel).

Figure 1. Flow chart of inclusion of high-risk prostate cancer patients treated by radical prostatectomy in the study. *Refers to treatment with antiandrogens, surgical or chemical castration therapy, 223Radium, and early or late chemotherapy (most commonly Docetaxel or Cabazitaxel).

Table 1. Characteristics of radical prostatectomy (RP) specimens in the 68Ga-PSMA PET/CT cohort and in the 99mTc bone scintigraphy and CT-TAP cohort.

Table 2. Baseline and clinicopathological characteristics of the 68Ga-PSMA PET/CT cohort and the 99mTc bone scintigraphy and CT-TAP cohort.

Figure 2. 68Ga-PSMA PET/CT compared with conventional imaging in relation to recurrence-free survival (RFS) in Kaplan-Meier curve analysis with 0.95 CI. Primary staging with 68Ga-PSMA PET/CT was significantly associated with a longer 5-year RFS rate compared with conventional imaging. The median duration of follow-up was 45.5 months in the 68Ga-PSMA PET/CT cohort and 100.3 months in the 99mTc bone scintigraphy and CT-TAP (thorax, abdomen, pelvis) group. The follow-up data of the conventional imaging cohort is censored at 60 months due to much longer follow-up time compared with the 68Ga-PSMA PET/CT cohort to improve visualization.

Figure 2. 68Ga-PSMA PET/CT compared with conventional imaging in relation to recurrence-free survival (RFS) in Kaplan-Meier curve analysis with 0.95 CI. Primary staging with 68Ga-PSMA PET/CT was significantly associated with a longer 5-year RFS rate compared with conventional imaging. The median duration of follow-up was 45.5 months in the 68Ga-PSMA PET/CT cohort and 100.3 months in the 99mTc bone scintigraphy and CT-TAP (thorax, abdomen, pelvis) group. The follow-up data of the conventional imaging cohort is censored at 60 months due to much longer follow-up time compared with the 68Ga-PSMA PET/CT cohort to improve visualization.

Data availability statement

Most data supporting the reported results are provided in the paper and further data are stored by the authors.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.